First patient enrolled in Gedea Biotech’s NEFERTITI Clinical Trial of pHyph for antibiotic-free treatment of women with bacterial vaginosis
PRESS RELEASE 2021-02-01 Lund, Sweden, February 2nd, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled the first patient in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). The…
Gedea on Top 21 list
Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list "The 21 European Biotech…
Gedea Biotech receives MHRA approval to initiate NEFERTITI Clinical Trial in the UK of pHyph for antibiotic-free treatment of women with bacterial vaginosis
Lund, Sweden, October 27, 2020. Gedea Biotech,today announces that it has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis…
Gedea Biotech gains ISO 13485: 2016 certification in preparation for CE marking and launch of antibiotic-free bacterial vaginosis treatment
Lund, Sweden, April 7, 2020. Gedea Biotech, an innovative women’s health company today received its certificate in accordance with ISO 13485: 2016…
82 % clinically cured in antibiotic-free treatment trial in women with bacterial vaginosis
PRESS RELEASE Lund, Sweden, March 11, 2020. Gedea Biotech, an innovative women’s health company today reported results from a clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of bacterial vaginosis (BV). In this open-label, single-armed, multi-center study, 82% of…
International Women´s Day 2020
This year´s International Womon´s Day, Gedea wants to support UN Women´s campaign “I am Generation Equality: Realizing Women’s Rights”. The Generation Equality campaign is bringing together people of every gender, age, ethnicity, race, religion and country, to drive actions that will create the…
Media coverage 2019
10 January 2020 In 2019 Gedea gained good traction in media, both Swedish and international. Rapidus, BioStock, Life Science Sweden, Läkemedelsmarknaden and other Swedish business/medtech media published articles about us. American BioSpace published no less than three press items on Gedea. We are…
Merry Christmas
In 2019, we conducted two clinical studies, developed the quality system, moved into new premises, received grants from SweLife and as a fantastic end to the year we could tell that we were granted 3 million Euro by the EU Horizon 2020. We look forward to 2020 together!
Swedish women’s health company Gedea Biotech awarded €3 M by EU’s Horizon 2020 to accelerate introduction of antibiotic-free treatment for vaginal infections
Gedea Biotech today announced that it has received €3 M from the EU program Fast Track to Innovation (FTI), part of Horizon 2020. The grant will fund completion of the clinical trial program and preparation work for market introduction of the company’s antibiotic-free treatment for vaginal…